|
|
 |
|
Viewing report
|
|
|
|
Profiles in Metastatic Breast Cancer
Panel Intelligence, LLC, Oct 2004
In 2003, approximately 40,000 deaths in the United States were attributed to breast cancer. While significant therapeutic advances for early-stage disease have emerged in recent years, an estimated 30% to 40% of all patients (in Western countries) ultimately develop metastatic breast cancer (MBC). Median survival for MBC patients is estimated at an all too brief two years, underscoring tremendous unmet need among the MBC population.
Profiles in Metastatic Breast Cancer spotlights for drug developers potential opportunities for clinical and commercial advances in MBC drug development. These potential opportunities are identified through insights derived from:
A qualitative online discussion among key opinion leaders
A quantitative survey and conjoint exercise completed by 100 community-based oncologists in the United States
This study will help clients understand therapeutic unmet needs and the product attributes and levels of performance that drive physician preference and prescribing behavior. Further, the study looks prospectively at promising novel therapeutic targets and investigational agents for MBC. Taken together, the components of Profiles in Metastatic Breast Cancer form an essential analytical tool for any organization contemplating the development, acquisition, or launch of an agent aimed at this vastly underserved patient population.
Key Points:
1. While community oncologists and KOLs provided similar responses in ranking toxicities from the physician perspective, the two groups diverged noticeably in ranking toxicities from the patient perspective
2. Although one of the longstanding assumptions of drug development is that oral administration is almost always preferable to IV/injectable administration, a tradeoff analysis among a large body of practicing oncologists here reveals that oral administration is of minimal importance
Customers who bought this item also bought
U.S. Breast Cancer Therapeutics Markets
Drug Targets for Breast Cancer
Breast Cancer - Therapeutic And Competitive Insights
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Approval Outlook for Avastin® as a Breast Cancer Treatment: A Survey of Fifty Oncologists (Survey)
Breast Cancer Drug Discoveries: What the Future Holds
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
Drug Targets for Breast Cancer
Lynn Sage Breast Cancer Symposium
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Breast Cancer Therapeutics - Global Strategic Business Report
Pipeline Insight: Breast Cancer - A Diverse & Increasingly Crowded Pipeline
|
|
|
|
